Hypha Discovery Ltd

Hypha collaborates with pharma/biotech and agrochemical groups in the following areas

1. Production of metabolites of clinical and preclinical stage compounds that are difficult to synthesise using metabolising microbes:
+ mg amounts for MetID, quantification standards
+ gram quantities for tox/pharmacological studies
+ includes glucuronides and chemically intractable hydroxyl derivatives 

Our microbial biotransformation service is also used to improve PK/solubility in hit-to-lead compounds 

2. Niche natural products hit-finding
Licensing access to Hypha's MycoDiverse natural products library. 
+ Used by biotech and pharma to find hit compounds against "difficult-to-hit" targets
+ Molecular weight range mostly between 200 and 400 DA
+ 50% novelty
+ Exclusive rights to develop and commercialise

3. Fermentation and purification of small molecules for semi-synthetic lead optimisation

Dr Liam Evans
CEO